{"id":"NCT00912925","sponsor":"Genzyme, a Sanofi Company","briefTitle":"Clinical Study of Aldurazyme in Patients With Mucopolysaccharidosis (MPS) I","officialTitle":"A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Multinational, Clinical Study of Recombinant Human Alpha L-Iduronidase In Patients With Mucopolysaccharidosis I","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2000-12","primaryCompletion":"2001-09","completion":"2001-09","firstPosted":"2009-06-03","resultsPosted":"2009-08-19","lastUpdate":"2015-04-07"},"enrollment":45,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Mucopolysaccharidosis I","Hurlers Syndrome","Hurler-Scheie Syndrome"],"interventions":[{"type":"BIOLOGICAL","name":"rhIDU (recombinant human-Alpha-L-Iduronidase)","otherNames":[]},{"type":"BIOLOGICAL","name":"Placebo","otherNames":[]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Aldurazyme treatment","type":"ACTIVE_COMPARATOR"}],"summary":"This study is being conducted to demonstrate the safety and clinical efficacy of Aldurazyme treatment in MPS I patients","primaryOutcome":{"measure":"Overall Change From Baseline to Week 26 in Percent Predicted Forced Vital Capacity (FVC)","timeFrame":"Baseline to Week 26","effectByArm":[{"arm":"Placebo","deltaMin":54.2,"sd":16},{"arm":"Aldurazyme Treatment","deltaMin":48.4,"sd":14.85}],"pValues":[]},"eligibility":{"minAge":"5 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":6},"locations":{"siteCount":4,"countries":["United States","Canada","Germany"]},"refs":{"pmids":["33874971"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":23},"commonTop":["Headache","Pyrexia","Diarrhoea","Vomiting","Rash"]}}